t4期鼻咽癌同步放化疗联合西妥昔单抗治疗的初步评价肿瘤学专业论文.docxVIP

高则OS越差，西妥昔治疗可能提升0S。鼻咽原发灶硬脑膜侵犯会明显降 高则OS越差，西妥昔治疗可能提升0S。鼻咽原发灶硬脑膜侵犯会明显降 低T4患者各生存结果，尤其是DMFS。西妥昔联合放化疗会增加T4期患者 的口腔黏膜反应和痤疮样皮疹，但在均在可接受范围之内，并不增加晚期 毒性反应。 关键词：鼻咽癌；调强适行放疗；放化疗；西妥昔单抗 万方数据 Clinical Clinical outcomes of Patients with stage T4 n asoPh aryngeal carcinoma treated with rituximab Plus radiotheraPy Abstract Objective：To explore the clinical efficacy and toxicity of cetuximab combined with chemotherapy and factors influencing the prognosis of T4 stage of comprehensive treatment of T4 nasopharyngeal carcinoma(NPC)．Methods and Materials：RetrosPectively collected in our hospital in 2006 January to 20 1 2 to December of T4 stage(UICC2002 staging)all cetuximab therapy and radical intensity．modulated radiotherapy (IMRT) in Patients with nasoPharyngeal carcinoma(NPC)received a total of 3 0 cases，as treatment group．Matching treatment groups of patients with age，sex，pathology，N ．dose ofoI radiotherapyradiotherapy andld chemotheraPchemotherapy screeneed’nin 2006ZU00 JanuarJ tO dose anuary December 20 1 2 to accept radical IMRT treatment and without any target to drug treatment of T4 nasoPharyngeal carcinoma Patients in 3 0 cases，as the control group．The median age was 42 years(1 7—69 years old)．The initial dose of rituximab was 400mg／m2 Per week，followed by 25 0mg／m2，a total of 4—1 3 times a week．Nasopharyngeal gross tumor volume(GTVnx)in a dose D95 74Gy 69．4-80．6Gy／30-3 7F，high—risk clinical target volume(CTV 1)in a dose D95 669y 60-70Gy／29-34F，low-risk clinical target volume(CTV2)in a dose D95 58Gy 45-62Gy／25-33F．The treating Physician is shown according to the CT／MRI target area，midcourse correction of target 1-6，and by the Physician with a suPerior audit．All Patients were treated with cisplatin based concurrent ．4． 万方数据 chemotherapy．78％Patients chemotherapy．78％Patients with cisplatin based neoadjuvant or adjuvant chemotherapy．The local regional control rate，survival and subgroups and toxicity of the two groups were statistically analyzed．Survival analysis using the K